14.00 - 14.15
Opening and welcome
Jarosław Czyż (Chair of the organising committee)
Antonio Risitano (Chair of the scientific committee)
14.15 - 15.35
SESSION 1: PNH overview
Chair: Jarosław Maciejewski, Antonio Risitano, Jens Panse
14.15 - 14.30
Natural history of PNH & Patophysiology
Jarosław Maciejewski
14.30 - 14.45
The fundamentals of IVH, EVH & BTH, including pharmacokinetic & pharmacodynamic BTH
Antonio Risitano
14.45 - 15.00
Thrombosis management in PNH
Richard Kelly
15.00 - 15.15
PNH & aplastic anaemia: an unmet need
Régis Peffault de Latour
15.15 - 15.35
Roundtable discussion
15.35 - 15.50
Coffee break
15.50 - 17.10
SESSION 2: C5 inhibition
Chair: Régis Peffault de Latour, Patrycja Mensah-Glanowska, Joanna Drozd-Sokołowska
15.50 - 16.05
C5 inhibition history, clinical trials on eculizumab and ravulizumab & real world evidence
Łukasz Szukalski
16.05 - 16.15
Case report: Challenging patient treated with ravulizumab
Delia Soare
16.20 - 16.35
Battling with PNH from physician’s perspective
Barbara Pečovnik
16.40 - 16.55
Crovalimab clinical trials data
Phillip Scheinberg
16.55 - 17.05
Case report: Challenging patient treated with crovalimab
Justyna Kozińska
17.10 - 17.30
Coffee break
17.30 - 18.40
SESSION 3: PNH worldwide & varia
Chair: Agnieszka Piekarska, Anna Szmigielska-Kapłon, Jarosław Czyż
17.30 - 17.40
PNH in US & Canada
Jarosław Maciejewski
17.40 - 17.50
PNH in Western Europe
Jens Panse
17.50 - 18.00
PNH in Central-Eastern Europe
Jaroslav Čermák
18.00 - 18.10
Is there a place for alloHSCT in PNH?
Joanna Drozd-Sokołowska
18.10 - 18.35
PNH in Ukraine & discussion
Olena Kyselova
18.35 - 18.40
Day 1 wrap-up
Jarosław Czyż